Comparable stake leader
—
SEC ownership of ANTARES PHARMA, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001016169.
Disclosed value leader
—
Comparable rows
0/0
Latest evidence
—
- Parsed ownership sources
-
13F, 13D/G, and Forms 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Issuer CIK
- 0001016169
- Issuer location
- Ewing, NJ
Ownership snapshot
Top shareholders of ANTARES PHARMA, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
—
Disclosed value leader
—
Comparable rows
0/0
Latest evidence
—
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to ANTARES PHARMA, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Thomas J. Garrity
Net 12M change
$0
Latest report
24 May 2022
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Thomas J. Garrity | Director | Mixed | 24 May 2022 | |||
| Anton Gueth | Director | Mixed | 24 May 2022 | |||
| Robert F. Apple | President and CEO, Director | Mixed | 24 May 2022 | |||
| Peter J. Graham | EVP, General Counsel, Chief Compliance Officer and Secretary | Mixed | 24 May 2022 | |||
| Fred M. Powell | Executive Vice President & CFO | Mixed | 24 May 2022 | |||
| Leonard S. Jacob | Director | Mixed | 24 May 2022 | |||
| Peter C. Richardson | EVP, Research and Development and Chief Medical Officer | Mixed | 24 May 2022 | |||
| Robert P. Roche Jr. | Director | Mixed | 24 May 2022 | |||
| Karen L. Smith | Director | Mixed | 24 May 2022 | |||
| Peter Greenleaf | Director | Mixed | 24 May 2022 | |||
| Carmen B. Volkart | Director | Mixed | 24 May 2022 |
Recent insider transactions for ANTARES PHARMA, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.